This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
GVAX Prostate Cancer Vaccine
Johnson & Johnson
Drug Names(s): BioSante Prostate Cancer Vaccine, CG1940 and CG8711, galgenprostucel-l
Description: GVAX vaccine for prostate cancer is comprised of irradiated prostate cancer cells that have been genetically modified to continually produce granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in augmenting the body's immune response to vaccines.
Cell Genesys and Takeda
In March 2008, Cell Genesys and Takeda Pharmaceutical announced that the companies have formed a global alliance for the development and commercialization of GVAX immunotherapy for prostate cancer.
Under the agreement, in exchange for exclusive worldwide commercial rights to GVAX immunotherapy for prostate cancer, Takeda will pay Cell Genesys an upfront payment of $50 million and additional milestone payments totaling up to $270 million relating to regulatory approval and commercialization of GVAX immunotherapy for prostate cancer in the United States, European Union and Japan. Takeda will pay Cell Genesys tiered, double-digit royalties based on net sales of GVAX immunotherapy for prostate cancer in the United States and flat double-digit royalties based on net sales of the product in all other regions. From this point forward, Takeda will pay for all external development costs associated with the ongoing Phase III clinical development of GVAX...See full deal structure in Biomedtracker
Partners: ANI Pharmaceuticals, Inc. Aduro Biotech
GVAX Prostate Cancer Vaccine News
Pink Sheet Cell Genesys GVAX second pivotal begins
Additional information available to subscribers only: